Healthcare's Quiet Reporting Season: Three Stocks Nobody Talked About
Healthcare barely registered this reporting season. Three mid-caps show 32-177% upside to fair value. Healius carries the second-largest upside gap across all 278 companies in our coverage.
February 2026 reporting season has been dominated by banks posting record earnings, gold miners riding US$2,900 spot prices, and the usual debate over whether CBA deserves to trade at 24 times earnings. Healthcare barely registered. That is worth examining, because our pipeline analysis of 278 ASX-listed companies found three healthcare mid-caps sitting on valuation gaps between 31% and 177%, and one of them, Healius, carries the second-largest upside gap in the entire coverage universe.
The three companies are Healius (HLS), a pathology network operator priced at A$0.69 against a fair value of A$1.91; EBOS Group (EBO), the company that delivers roughly three in four prescription medicines dispensed in Australia, priced at A$20.08 against A$35.57; and Sonic Healthcare (SHL), the global diagnostics leader, at A$23.13 against A$30.43. All three reported results in line with or ahead of guidance. None generated meaningful market commentary. The reasons for the silence are different in each case, but the pattern is consistent: the market's attention was elsewhere, and these stocks were left behind while the attention economy rewarded momentum names with double-digit earnings beats.
For context, CSL (HOLD, A$152 vs A$132 fair value), Cochlear (HOLD, A$200 vs A$123), and ResMed (BUY, US$128 vs US$188) complete the ASX healthcare picture, but the mid-cap trio above is where the mispricing concentrates. The large-cap names attract deep institutional coverage and trade at premium multiples that reflect that coverage. The mid-caps, where the actual valuation gaps sit, attract a fraction of the attention and a fraction of the capital.
Scorecard
| Company | Rating | Price | Fair Value | Gap | Quality | Key Metric |
|---|---|---|---|---|---|---|
| HLS (Healius) | BUY | A$0.69 | A$1.91 | +177% | 5.5/10 | EV/EBITDA 3.9x vs sector 9.5x |
| EBO (EBOS Group) | BUY | A$20.08 | A$35.57 | +77% | 7.5/10 | 75-80% wholesale pharma market share |
| SHL (Sonic Healthcare) | BUY | A$23.13 | A$30.43 | +31% | 6.9/10 | EV/EBITDA 7.9x vs 11.0x peer median |
HLS: The Turnaround the Market Has Already Priced as Failed
Healius operates Australia's second-largest pathology network, collecting and processing specimens through 2,200 collection centres and accredited laboratories funded almost entirely through Medicare. At A$0.69, the market has priced this as a permanently impaired business. The numbers from the H1 FY26 result suggest otherwise: revenue grew 4.4% to A$688 million, and the T27 cost programme delivered A$18 million in annualised savings against a A$15-20 million target. Labour costs, the single largest line item, fell from 52% to 49.3% of revenue between the first and second quarters.
The simplification of the business is now complete. The May 2025 sale of the Lumus Imaging division for A$965 million eliminated all debt, leaving Healius with net cash and full operational focus on pathology. Agilex Biolabs, the contract research arm retained after the Lumus sale, grew revenue 16% and EBIT 145% in the half, a quieter but genuine proof point that the simplified business is gaining traction. The genomics testing pipeline is growing at approximately 25% annually, though from a base that remains under 5% of group revenue. The company holds A$48.3 million in franking credits that cannot be deployed until EBIT recovers meaningfully, meaning no dividend is forecast through at least FY28.
The valuation gap is extreme, and the mathematics of the gap are instructive. At 3.9 times EV/EBITDA (enterprise value divided by earnings before interest, tax, depreciation and amortisation), Healius trades at a 59% discount to the 9.5 times sector median. Sonic Healthcare operates 10% EBIT margins in the same Australian pathology market with the same Medicare reimbursement structure, confirming that the economics support much higher profitability than the 0.9% EBIT margin Healius currently achieves. EBIT remains suppressed not primarily by weak trading but by A$222 million in annual depreciation, the legacy of decades of network investment captured through lease accounting. The EBITDA margin of 17.8% tells a cleaner story: the underlying operations generate cash, but the depreciation burden from the collection centre network overwhelms the reported earnings line.
Our probability-weighted fair value of A$1.91 uses three scenarios. The base case (55% probability) values the company at A$2.15, assuming the T27 programme delivers its 8% EBIT margin target and the Medicare fee schedule provides at least partial offset for Fair Work Commission costs. The bear case (30% probability) at A$1.18 assumes no Medicare fee relief and EBIT margins capped at 5-6%, and even that scenario sits 71% above today's price. The severe case (15% probability) at A$0.47 models a complete turnaround failure. Combining these produces A$1.91 and an upside-to-downside asymmetry of 2.3 to 1 from current levels. The current market price sits below all three probability-weighted scenarios except the severe case, which implies a permanently broken business. The business quality score of 5.5 out of 10 reflects that return on invested capital (ROIC, a measure of how much profit a company generates per dollar of capital employed) currently sits at just 2% against a 9% cost of capital. The company is destroying value today. The investment case is that the destruction is temporary rather than structural, and the evidence from H1 FY26 supports that reading.
The single biggest risk to the thesis is identifiable and time-bound. The Fair Work Commission gender pay ruling adds an estimated A$20-30 million per year in structural labour costs through to 2031. If the government declines to adjust the Medicare fee schedule in the November 2026 update, as it has historically done when pathology costs have risen, the T27 margin target becomes arithmetically unreachable: EBIT margins stay capped around 5-6% rather than 8%, and fair value falls 25-35% from the base case. Our model assigns 35% probability to that outcome. Investors should treat November 2026 as a hard checkpoint: no fee relief by December 2026, combined with confirmed FWC costs above A$25 million annually, warrants moving the bear case weighting to 50% and the fair value estimate down to approximately A$1.40. The moat is real but narrow, with an estimated duration of five to seven years before telehealth disruption and Sonic's scale advantage erode it further.
EBO: A$12 Billion in Revenue, Almost Zero Market Attention
EBOS Group is the kind of business that functions as infrastructure rather than a stock. It distributes pharmaceuticals, medical devices, and consumer health products to pharmacies, hospitals, and aged-care facilities across Australia and New Zealand, handling roughly 75-80% of wholesale prescription volume through a A$4.2 billion government Community Service Obligation contract. It also owns a growing pet food and veterinary business through the SVS acquisition. At A$20.08, the stock trades near a five-year low despite a business quality score of 7.5 out of 10 and ROIC of 12.9% comfortably exceeding its 7.5% WACC (weighted average cost of capital, the blended return the market requires).
The H1 FY26 result showed revenue up 13% to A$6.8 billion, driven by new hospital and aged-care contract wins, the full contribution of the SVS veterinary acquisition, and accelerating GLP-1 (obesity medicine) prescription volumes flowing through the network. PBS (Pharmaceutical Benefits Scheme) prescription volumes are growing at 4-6% purely from demographics and new medicine listings, providing a recurring volume floor that does not depend on economic conditions. Management reaffirmed full-year EBITDA guidance of A$615-635 million, consistent with our A$625 million estimate. EPS is projected to grow from A$1.05 in FY25 to A$1.33 in FY26 and A$1.73 by FY28, with dividends stepping from A$1.02 to A$1.40 over the same period at an 82% payout ratio, supporting a 5.1% dividend yield at today's price.
The reason margins remain compressed, and the reason the stock sits where it does, is a once-in-a-generation distribution centre rebuild. EBOS has been running two parallel distribution networks while completing a A$360 million national DC programme. Six of eight new centres are now operational and on-budget, meaning the transition costs reverse mechanically into FY27. This is not a margin problem that requires management heroics to solve. The parallel network costs are visible, quantified, and disappearing on a known schedule. Capital expenditure falls from A$146 million in FY25 toward A$93 million in FY28 as the build programme winds down, converting directly to free cash flow growth from A$226 million this year to A$385 million in FY28. That trajectory represents a 70% increase in free cash flow over two years, driven entirely by the completion of capital spending that is already underway.
Our fair value of A$35.57 is derived from a probability-weighted blend of DCF (55% weight), trading multiples (35%), and transaction comparables (10%), using a 7.5% WACC and 3.0% terminal growth rate. The single most important variable is the terminal EBITDA margin: each 100 basis points of movement shifts fair value by roughly A$11.50 per share. At 9.8 times trailing EV/EBITDA against a 12-13 times peer range, the discount reflects scepticism about the recovery timeline and a persistent dual-listing discount (EBOS reports in NZD, is listed on both the NZX and ASX, and attracts limited Australian institutional coverage) rather than deteriorating fundamentals. The market is implying a required return of roughly 10.5% against our CAPM-derived 7.5%, a 300 basis point gap that accounts for almost the entire A$15 difference between the current price and fair value. The bull case of A$46.20 (20% probability) assumes full margin recovery plus GLP-1 volumes accelerating above base assumptions; the bear case of A$30.10 (25% probability) implies 50% upside from today's price even if the recovery timeline extends by 12 months.
The competitive moat is wide. With 75-80% of wholesale pharmaceutical distribution locked through the government CSO agreement, a competitor would need to replicate a national cold-chain logistics network, secure government accreditation, and win market share against an incumbent whose economics improve with every additional prescription routed through the existing infrastructure. The moat's weakness is that it protects a low-margin business: EBITDA margins run at 4.5-4.8% and are unlikely to exceed 5% structurally, meaning the investment return is driven by volume and capital efficiency rather than pricing power. Leverage at 2.2 times net debt to EBITDA leaves limited margin for error if the DC rebuild costs overrun, though six of eight centres being complete and on-budget substantially reduces that risk.
The April 2026 Investor Day is the near-term inflection point. New CEO Adam Hall will present his first strategic framework, a credibility event that the market is watching closely given the leadership transition. The August 2026 full-year results will provide the first clean read on whether DC cost reversal is tracking as expected: if Healthcare operating costs as a proportion of revenue fall below 7.5% in that result, the structural thesis is confirmed.
SHL: Growing Faster Than Peers, Valued as If It Is Not
Sonic Healthcare is the largest pathology provider in Australia (approximately 45% market share) and, after acquiring LADR in 2025, holds roughly 25% of the German market. Revenue of A$9.6 billion in FY25 is forecast to reach A$12.3 billion by FY28, with organic volume growth of 5% in constant currency running well ahead of the 1-2% that global diagnostic peers manage. Yet Sonic trades at 7.9 times EV/EBITDA, a 39% discount to the 11.0 times peer median, the widest gap in five years. The business quality score of 6.9 out of 10 reflects a genuine competitive moat built on what Sonic calls "Medical Leadership": clinician-run labs with sub-5% GP attrition rates, a model that no competitor has replicated in 30 years and that generates a 100-150 basis point EBITDA margin premium over domestic rival Healius.
The H1 FY26 result showed the business operating at two speeds. Constant-currency revenue rose 10% and organic volume grew 5%, demonstrating that the underlying engine is healthy. But the Australian dollar appreciated, stripping roughly A$185 million from reported revenue translation, and LADR integration costs weighed on the reported EBITDA margin. The adjusted margin of 18.1% tells a cleaner story than the reported 16.7%, though both figures are real consequences of the same strategic choices. Management guided to A$1.87-1.95 billion EBITDA for the full year. The dividend yields 4.1% at current prices, partially franked, with dividends stepping from A$0.95 to A$1.05 over three years as the payout ratio declines from 67% to 59%.
The discount to peers reflects three legitimate concerns, and understanding them is central to sizing the opportunity. First, CEO Newcombe has been in the role for less than twelve months following the Goldschmidt era, and the market has not yet calibrated his credibility. Second, three concurrent integrations (LADR in Germany, HWE hub lab in the UK, and an esoteric testing pivot in the US) stretch management bandwidth in a way that single-integration companies do not face. Third, the US segment produced zero organic growth in H1 FY26, raising questions about whether the repositioning toward higher-complexity testing will actually generate share gains or merely prevent further losses. Two consecutive halves of negative US organic growth would signal structural market share loss rather than tactical repositioning, and would warrant reassessing the thesis.
Our fair value of A$30.43 reflects a base case (60% probability) of A$35.68 where LADR synergies flow through as expected and the US stabilises at low single-digit organic growth, combined with a bear case (30% probability) of A$22.82 where AUD appreciation continues, LADR synergies disappoint, and US organic growth turns negative. The severe case (10% probability) at A$13.52 models a full integration failure with write-downs. The 90% confidence interval runs from A$21.90 to A$39.00. The bear case of A$22.82 approximately equals today's price, meaning the market is already pricing near-worst-case execution. The return on invested capital runs at 8.5%, which barely clears the 7.8% cost of capital, reflecting a genuine weakness: the capital deployed on acquisitions generates a thin return spread, and the new CEO is untested through a downturn. The moat is real, but the return on the capital spent to build it is modest.
The investment case is a gap-closing trade with specific catalysts and a bounded downside. Free cash flow is compressed by integration capital expenditure running at 7% of revenue versus a normalised 5%, but that unwinds through FY27-28 as the LADR and HWE hub-lab builds complete, projecting FCF recovery from A$620 million to A$950 million. That effectively doubles the free cash flow yield on today's price. The LADR synergy quantification, expected at FY2027 results, is the re-rating trigger: if Germany's adjusted EBITDA margin tracks toward 18%, the peer discount narrows materially. A reading below 16% would raise questions about whether the synergies are structural or aspirational. The diagnostics industry's structural tailwind provides the patience premium: Australia's 65-plus cohort expands at 3% annually, government reimbursement provides a permanent volume floor that no recession has meaningfully disrupted, and test utilisation rates rise with each year of population ageing. Sonic provides the purest ASX-listed exposure to global diagnostics consolidation, paying a 4.1% yield while investors wait for the re-rating.
Why Healthcare Got Overlooked
Healthcare mid-caps share characteristics that make them structurally easy to ignore during a reporting season dominated by momentum. They tend to grow at GDP-plus rates rather than double digits, their revenue is anchored by government fee schedules rather than pricing power, and their turnaround catalysts operate on 12-24 month timelines rather than quarter-to-quarter beats. The contrast with the large-cap healthcare names is instructive: CSL at A$152 trades above our A$132 fair value, and Cochlear at A$200 sits 62% above our A$123 fair value. The market has no trouble paying attention to those names because they are index heavyweights with deep institutional coverage. The mid-caps, where the actual mispricing sits, attract a fraction of the coverage and a fraction of the capital.
The common thread across HLS, EBO, and SHL is that each stock's discount has an identifiable, time-bound explanation rather than a permanent structural impairment. Healius is a turnaround with cost savings tracking ahead of schedule. EBOS has a distribution centre rebuild completing on budget. Sonic has integration capex that mechanically unwinds. In each case, the market appears to be treating temporary margin compression as permanent, and the August 2026 reporting cycle, when all three deliver full-year results, is the first real test of whether that scepticism is justified.
What Would Change Our View
More optimistic on HLS: The November 2026 Medicare Benefits Schedule update is the highest-leverage event. A partial fee offset for Fair Work Commission gender pay costs adds an estimated A$0.45 per share to fair value, moving the base case from A$2.15 to approximately A$2.60. Labour costs sustaining below 49% of revenue through the full FY26 year would confirm that the T27 programme is delivering structural rather than one-off savings. Agilex Biolabs revenue exceeding A$50 million on a full-year basis would provide evidence that the contract research business can become a meaningful earnings contributor rather than rounding error. Each 100 basis points of EBIT margin improvement above the current 0.9% adds approximately A$0.30 per share to fair value.
More optimistic on EBO: Healthcare operating costs falling below 7.5% of revenue in the August 2026 full-year result would confirm the DC cost reversal thesis. Free cash flow reaching A$350 million or above in FY27, ahead of our A$326 million estimate, would demonstrate that capital expenditure is declining faster than modelled. The April 2026 Investor Day could serve as a credibility catalyst if new CEO Adam Hall articulates margin targets that compress the 300 basis point gap between the market-implied 10.5% required return and our 7.5% WACC. GLP-1 prescription volumes accelerating above 10% growth would flow directly through the EBOS distribution network, adding revenue with minimal incremental cost.
More optimistic on SHL: Germany's adjusted EBITDA margin tracking toward 18% in the FY2027 results would confirm LADR procurement savings and lab rationalisation are flowing through as expected, and is the single most credible catalyst for closing the peer discount. US organic growth recovering to positive 2-3% for two consecutive halves would remove the concern that the esoteric repositioning is failing. Each 100 basis points of EBITDA margin expansion adds approximately A$2.50 per share to our fair value. An AUD depreciation toward 0.60 against the USD would add approximately A$1.80 per share through translation effects alone, given that over 60% of Sonic's revenue is earned offshore.
Less optimistic on all three: A government decision to freeze or cut Medicare fee schedules in the November 2026 update would directly impair both HLS and SHL, as both derive the majority of their Australian revenue from government reimbursement. For Healius specifically, a freeze combined with confirmed FWC costs above A$25 million annually would cap the turnaround well below the T27 targets. For EBOS, a broader PBS funding squeeze or CSO renegotiation that reduces the per-script distribution margin would compress the already thin 4.5-4.8% EBITDA margins further. A sustained AUD appreciation above 0.70 against the USD would continue eroding Sonic's offshore earnings translation while leaving the underlying business unaffected, widening the gap between operational performance and reported results. The February 2026 RBA rate increase to 3.85% and above-target inflation at 3.8% confirm that the macro environment supporting current equity valuations is not guaranteed to persist. Healthcare mid-caps are less directly exposed to rate sensitivity than consumer discretionary, but their recovery timelines of 12-24 months mean investors bear the opportunity cost of capital allocated to names that may take longer to re-rate than the broader market takes to correct.
Bottom Line
Three healthcare mid-caps delivered reporting season results consistent with their recovery trajectories, and all three remain priced as though the recoveries will not materialise.
Healius at A$0.69 against a fair value of A$1.91 represents the most extreme asymmetry in the group. At 3.9 times EV/EBITDA, with even the bear case of A$1.18 sitting 71% above the current price, the stock prices a scenario worse than our worst probable outcome. The turnaround evidence is early but directional: A$18 million in annualised savings ahead of the A$15-20 million target, labour costs falling from 52% to 49.3%, and a simplified pure-play pathology business with net cash. The entry point for investors willing to bear the 15% severe-case risk of A$0.47 is at or below current levels; the checkpoint is the November 2026 Medicare schedule update, which will determine whether the margin recovery path is open or capped.
EBOS at A$20.08 against a fair value of A$35.57 is the most operationally straightforward of the three. The 77% gap is not built on heroic assumptions: revenue grows below GDP-plus-2%, terminal margins sit below the historical average, and three catalysts (DC completion, CSO funding uplift, capex decline) are contractually locked or physically underway. Free cash flow growth from A$226 million to A$385 million over two years, combined with a 5.1% dividend yield while waiting, makes this a value case with a known timeline. The entry point that provides a margin of safety against the dual-listing discount persisting is below A$22, which preserves approximately 60% upside to fair value.
Sonic at A$23.13 against a fair value of A$30.43 is the highest-quality franchise of the three, growing organic volume at 5% against peers managing 1-2%, yet trading at the widest peer discount in five years. The bear case of A$22.82 approximately matches today's price, meaning the downside is bounded and the 4.1% partially franked dividend yield provides income while waiting for the LADR synergy data in FY2027. The entry point that aligns the risk-reward with the integration uncertainty is below A$24, which provides approximately 27% upside to fair value while pricing in the possibility that the US segment continues to stall and LADR synergies take longer than modelled.
The common requirement across all three is patience: the catalysts are real but the timelines are measured in halves, not weeks, and investors who need near-term earnings momentum will find the wait uncomfortable.
Analysis generated by the Alpha Insights AI research pipeline. All fair values are point estimates subject to model uncertainty. This is not financial advice. Do your own research before making investment decisions.